US2005025767A1PendingUtilityA1

Therapeutic agents for multiple sclerosis

23
Assignee: JUN NISHIHIRAPriority: Nov 30, 2001Filed: May 27, 2004Published: Feb 3, 2005
Est. expiryNov 30, 2021(expired)· nominal 20-yr term from priority
Inventors:Jun Nishihira
A61P 43/00A61P 25/00C07K 16/24A61K 2039/505
23
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides therapeutic agents for multiple sclerosis containing an antibody binding to macrophage migration inhibitory factor (MIF) as an active ingredient, and the therapeutic agents for multiple sclerosis of the present invention are effective for the conventional form of multiple sclerosis (C-MS) or the optic-spinal form of multiple sclerosis (OpS-Ms).

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for multiple sclerosis containing an antibody binding to macrophage migration inhibitory factor (MIF) as an active ingredient.  
     
     
         2 . A therapeutic agent for multiple sclerosis containing an antibody binding to macrophage migration inhibitory factor (MIF) to inhibit the binding of macrophage migration inhibitory factor (MIF) to its receptors as an active ingredient.  
     
     
         3 . The therapeutic agent for multiple sclerosis of  claim 1  wherein multiple sclerosis is the conventional form of multiple sclerosis (C-MS) or the optic-spinal form of multiple sclerosis (OpS-Ms).  
     
     
         4 . The therapeutic agent for multiple sclerosis of  claim 2  wherein multiple sclerosis is the conventional form of multiple sclerosis (C-MS) or the optic-spinal form of multiple sclerosis (OpS-Ms).

Join the waitlist — get patent alerts

Track US2005025767A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.